Ketoconazole + Tromethamine + Disodium Edta Dihydrate

Verify with FDA CVM →

76 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
76
Total Reports
1
Deaths Reported
130.0%
Death Rate

Active Ingredients

Ketoconazole + Tromethamine + Disodium Edta Dihydrate

Administration Routes

Auricular (Otic)UnknownOther

Species Affected

Dog 75
Unknown 1

Most Affected Breeds

Terrier - Yorkshire 7
Retriever - Labrador 6
Shepherd Dog - Australian 5
Pug 4
Spaniel - Cocker American 3
Poodle (unspecified) 3
Pit Bull 3
Crossbred Canine/dog 3
Maltese 3
Poodle - Miniature 3

Most Reported Reactions

Lack of efficacy - NOS 17
Vomiting 10
Head tilt - ear disorder 9
Ocular discharge 9
Ataxia 8
Behavioural disorder NOS 8
Facial paralysis 7
Nystagmus 7
Vocalisation 6
Hearing decreased 6
Ear infection NOS 6
Lethargy (see also Central nervous system depression in Neurological) 6

Outcome Breakdown

Outcome Unknown
38 (50.7%)
Ongoing
26 (34.7%)
Recovered/Normal
8 (10.7%)
Recovered with Sequela
2 (2.7%)
Died
1 (1.3%)

Data Summary

Metric Value
Total adverse event reports 76
Reports involving death 1
Case-fatality rate (reported events) 130.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Ketoconazole + Tromethamine + Disodium Edta Dihydrate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 76 adverse event reports referencing Ketoconazole + Tromethamine + Disodium Edta Dihydrate, including 1 reports in which the animal died — a 130.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Ketoconazole + Tromethamine + Disodium Edta Dihydrate. Reported administration routes include Auricular (Otic), Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Ketoconazole + Tromethamine + Disodium Edta Dihydrate reports are Dog (75 reports), Unknown (1 reports), with Dog accounting for the largest share. Within those species, Terrier - Yorkshire (7), Retriever - Labrador (6), Shepherd Dog - Australian (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Ketoconazole + Tromethamine + Disodium Edta Dihydrate are Lack of efficacy - NOS (17), Vomiting (10), Head tilt - ear disorder (9), Ocular discharge (9). Of the 75 reports with a coded outcome, Outcome Unknown is the leading category at 50.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Ketoconazole + Tromethamine + Disodium Edta Dihydrate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial